Metabolic profile response to administration of epigallocatechin-3-gallate in high-fat-fed mice

Carregando...
Imagem de Miniatura

Data

2014-08-12

Autores

Moreno, Mayara Franzoi
De Laquila, Rachel
Okuda, Marcos Hiromu
Lira, Fabio Santos [UNESP]
Morais Honorato de Souza, Gabriel Inacio de
Souza, Claudio Teodoro de
Telles, Monica Marques
Ribeiro, Eliane Beraldi
Oller do Nascimento, Claudia Maria
Oyama, Lila Missae

Título da Revista

ISSN da Revista

Título de Volume

Editor

Biomed Central Ltd

Resumo

Background: Obesity is associated with increased adipose tissue and glucose intolerance. High-fat diets (HFDs) are known to induce obesity and increase proinflammatory adipokines. The consumption of green tea may improve the health of obese individuals because it contains a potent antioxidant that has effects on body weight, energy expenditure and serum cholesterol concentrations.Methods: We examined the effects of epigallocatechin-3-gallate (EGCG) (50 mg/kg body weight per day) or saline after 30 or 60 days of treatment. Mice were distributed into four groups: 1) NS: normolipidic diet receiving saline; 2) NE: normolipidic diet receiving EGCG; 3) HFS: high-fat diet receiving saline; 4) HFE: high-fat diet receiving EGCG.Results: We observed that administration of a HFD plus EGCG treatment for 60 days reduced delta weight, the relative weights of the mesenteric adipose tissue (MES), retroperitonial adipose tissue (RET), epididymal adipose tissue (EPI), the sum of the adipose tissues (SAT), reduced triacylglycerol (TG) and improved both high-density lipoprotein (HDL) cholesterol levels and the adiponectin/STA ratio when compared with HFS.Conclusions: Our results suggest that the chronic administration of EGCG (60 days) promoted a significant improvement in glucose tolerance, decreased adipose tissue deposits, weight mass, TG and HDL-C only when associated with high-fat diet treatment.

Descrição

Palavras-chave

High-fat diet, Adipokines, Adipose tissue, Inflammation

Como citar

Diabetology & Metabolic Syndrome. London: Biomed Central Ltd, v. 6, 7 p., 2014.